Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
GT Biopharma, Inc. GTBP
$0.30
-$0.01 (-1.94%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
12362553.00000000
-
week52high
3.29
-
week52low
0.26
-
Revenue
0
-
P/E TTM
0
-
Beta
0.86020700
-
EPS
-0.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 24 мая 2021 г. | |
| B. Riley FBR | Buy | 13 апр 2021 г. | |
| Roth Capital | Buy | 17 мар 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 13 сент 2022 г. |
| EF Hutton | Hold | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SHROTRIYA RAJESH C MD | A | 500000 | 500000 | 27 янв 2023 г. |
| Breen Michael Martin | A | 500000 | 500000 | 27 янв 2023 г. |
| Wendel Bruce | A | 500000 | 500000 | 27 янв 2023 г. |
| Ohri Manu | A | 500000 | 500000 | 27 янв 2023 г. |
| Breen Michael Martin | A | 50000 | 50000 | 15 июл 2022 г. |
| Breen Michael Martin | A | 606218 | 278058 | 15 июл 2022 г. |
| Ohri Manu | A | 200000 | 200000 | 15 июл 2022 г. |
| Ohri Manu | A | 100000 | 100000 | 15 июл 2022 г. |
| Ohri Manu | D | 0 | 100000 | 15 июл 2022 г. |
| Ohri Manu | A | 100000 | 100000 | 15 июл 2022 г. |
Новостная лента
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
GlobeNewsWire
08 сент 2022 г. в 07:30
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright's 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event.
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
GlobeNewsWire
12 мая 2022 г. в 08:00
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright's Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida.
GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences
PRNewsWire
24 февр 2022 г. в 07:30
BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022) Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE) Abstract Number: 250 Session: Immunotherapy Presentation Type: Poster Session Date and Time: March 7, 9:20AM (CET) (On-demand e-poster display) Location: Virtual Poster Board Number: 17P 48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022) Title: A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number: AS-EBMT-2022-00508 Session: New Drugs- and Cell-Based Immune Therapies Presentation Type: Poster Session Date and Time: March 19, 2022, 9:50 AM (CET) Location: Prague Congress Center, Czech Republic Poster Board Number: P153 American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022) Title: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM – 5:00 PM Location: Ernest N.
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference
PRNewsWire
20 янв 2022 г. в 07:30
BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B.
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
Seeking Alpha
15 ноя 2021 г. в 01:44
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness